Skip to main content Scroll Top

Oral Communications

  • Home
  • Oral Communications
Clinical Trials on Alzheimer’s Disease (CTAD CHINA)
Clinical Trials on Alzheimer’s Disease (CTAD CHINA)
Alzheimer Oral Communications
24 October 2023
Clinical Trials on Alzheimer’s Disease (CTAD CHINA)
The RECOVERY study: first results of a pilot clinical trial to evaluate brain photobiomodulation in acute concussion in sportspeople
ISSC
The RECOVERY study: first results of a pilot clinical trial to evaluate brain photobiomodulation in acute concussion in sportspeople
Concussions Oral Communications
13 October 2023
The RECOVERY study: first results of a pilot clinical trial to evaluate brain photobiomodulation in acute concussion in sportspeople
15th International Conference on Alzheimer’s Disease & Parkinson’s disease (AD/PD) 2021, virtual conference
15th International Conference on Alzheimer’s Disease & Parkinson’s disease (AD/PD) 2021, virtual conference
Alzheimer Oral Communications
16 September 2021
15th International Conference on Alzheimer’s Disease & Parkinson’s disease (AD/PD) 2021, virtual conference
Photobiomodulation at the Level of Single Neural Cells in Culture
Photobiomodulation at the Level of Single Neural Cells in Culture
Alzheimer Oral Communications
2 January 2021
Photobiomodulation at the Level of Single Neural Cells in Culture
Relevance of photobiomodulation technique in AD treatment
Relevance of photobiomodulation technique in AD treatment
Alzheimer Oral Communications
5 November 2020
Relevance of photobiomodulation technique in AD treatment
Alzheimer’s disease and gut microbiota: a potential for prevention and treatment
Alzheimer’s disease and gut microbiota: a potential for prevention and treatment
Alzheimer Oral Communications
2 July 2019
Alzheimer’s disease and gut microbiota: a potential for prevention and treatment
Neuroprotective effect of novel photobiomodulation technology reduces microbiota dysbiosis in the Aβ25-35 mouse model
Neuroprotective effect of novel photobiomodulation technology reduces microbiota dysbiosis in the Aβ25-35 mouse model
Alzheimer Oral Communications
30 January 2019
Neuroprotective effect of novel photobiomodulation technology reduces microbiota dysbiosis in the Aβ25-35 mouse model
Designing a unique treatment protocol by assessing efficient photonic and magnetic emission parameters on an Alzheimer’s disease animal model
Designing a unique treatment protocol by assessing efficient photonic and magnetic emission parameters on an Alzheimer’s disease animal model
Alzheimer Oral Communications
25 January 2019
Designing a unique treatment protocol by assessing efficient photonic and magnetic emission parameters on an Alzheimer’s disease animal model
The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis
The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis
Alzheimer Oral Communications
6 June 2018
The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis